Cagrilintide
Product Overview
Cagrilintide (AM833) is a long-acting synthetic analogue of human amylin developed by Novo Nordisk and currently in clinical development. Scientific literature and clinical trials have examined it in combination with semaglutide (CagriSema) for metabolic conditions including obesity.
Research Information
Research interest includes amylin biology, metabolic regulation, and combination peptide therapy investigation.
Research Classification
Investigational — Not for human consumption. Not an approved medicine unless otherwise noted. Intended for laboratory, scientific, or clinical research contexts as permitted by applicable law.
